{"Clinical Trial ID": "NCT00320710", "Intervention": ["INTERVENTION 1:", "zoledronic acid every (q) 4 weeks", "Participants received 4mg zoledronic acid by intravenous infusion (IV) q 4 weeks.", "INTERVENTION 2:", "zoledronic acid q 12 weeks", "Participants received 4 mg zoledronic acid IV q 12 weeks and received placebo at Zometa IV at 4 week intervals between infusions of zoledronic acid q 12 weeks to keep them blind."], "Eligibility": ["Incorporation criteria:", "* Female patients 18 years of age. Breast cancer confirmed by bone metastases. Pre-treated with Zometa\u00ae, or Aredia (pamidronate) or all sequential regimens of both, for a minimum of 9 doses;", "- Exclusion criteria:", "\u2022 Abnormal renal function determined by serum creatinine levels; current active dental problems, including: continuous infection of teeth or jaw bone; current exposed bones in the mouth; and current or anterior diagnosis of osteonecrosis in the jaw.", "Recent (within 8 weeks) or planned dental or jaw surgery (e.g. extraction, implants).", "\u2022 Diagnosis of metabolic bone disease other than osteoporosis (e.g. Paget bone disease).", "Treatment with other experimental medicinal products within 30 days prior to randomisation.", "Other exclusion criteria defined by the Protocol may have been applied."], "Results": ["Performance measures:", "Proportion of patients with at least one skeleton event (ERS)", "A ERS has been defined as a pathological fracture (vertebral and non-vertebral), spinal cord compression, bone radiation or bone surgery.", "Time limit: 52 weeks", "Results 1:", "Title of arm/group: Zoledronic acid every (q) 4 weeks", "Description of the arm/group: Participants received 4mg zoledronic acid by intravenous infusion (IV) q 4 weeks.", "Total number of participants analysed: 200", "Type of measurement: Number", "Unit of measure: percentage of participants 22", "Results 2:", "Title of arm/group: Zoledronic acid q 12 weeks", "The participants received 4 mg zoledronic acid IV q 12 weeks and received placebo at Zometa IV at 4 week intervals between infusions of zoledronic acid q 12 weeks to maintain blindness.", "Total number of participants analysed: 203", "Type of measurement: Number", "Unit of measure: percentage of participants 23.2"], "Adverse Events": ["Undesirable Events 1:", "Total: 50/198 (25.25 per cent)", "Anemia 1/198 (0.51%)", "- Febrile neutropenia 1/198 (0.51%)", "- Leucocytosis 1/198 (0.51%)", "Leukopenia 2/198 (1.01%)", "Neutropenia 1/198 (0.51%)", "Pancytopenia 0/198 (0.00 %)", "Atrial fibrillation 0/198 (0.00 %)", "Congestive heart failure 0/198 (0.00 %)", "- Palpitations 0/198 (0.00 %)", "Pericardial infusion 1/198 (0.51%)", "- Superventricular tachycardia 1/198 (0.51%)", "Adverse Events 2:", "Total: 51/202 (25.25 per cent)", "Anemia 3/202 (1.49%)", "Febrile neutropenia 2/202 (0.99%)", "- Leucocytosis 0/202 (0.00 %)", "- Leucopenia 0/202 (0.00 %)", "Neutropenia 0/202 (0.00 %)", "Pancytopenia 1/202 (0.50%)", "Atrial fibrillation 1/202 (0.50%)", "Congestive heart failure 1/202 (0.50%)", "- Palpitations 1/202 (0.50%)", "1/202 (0.50%)", "- Superventricular tachycardia 1/202 (0.50%)"]}